ClinicalTrials.gg
CompletedNCT04238650Updated Mar 23, 2021Results posted

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

A Phase 1 interventional study of MB02 (Bevacizumab Biosimilar) and EU approved Avastin® in Healthy Volunteers, Male and Japanese, sponsored by mAbxience Research S.L.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (a Proposed Bevacizumab Biosimilar Drug) and EU Approved Avastin® in Japanese Healthy Male Volunteers.

During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

Read the detailed description

The primary PK parameter endpoint is AUC(0-∞) for bevacizumab. The secondary PK endpoints will include all other PK parameters for bevacizumab, including Cmax, tmax, t1/2, CL and AUClast.

The serum PK parameters of bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC[0-∞] and Cmax) and AUClast. The model will include a fixed effect for treatment and body weight as a covariate.

All other PK parameters will not be subject to inferential statistical analysis.

Estimates of geometric mean ratios together with the corresponding 90% confidence intervals (CI) will be derived for the comparisons of the PK parameters as follows:

  • MB02 versus EU Avastin®

A mixed effects model with treatment arm as fixed effect will be used to compare natural-logarithmic transformed PK parameters (AUC[0-∞+, AUClast and Cmax) between the two treatment arms (MB02 vs EU-approved Avastin®)

PK similarity between arms will be concluded if the 90% confidence intervals (CIs) for the geometric mean test/reference ratio of AUC(0-∞) fell within the predefined 0.80-1.25 bioequivalence interval.

All AEs will be listed and summarised using descriptive methodology. All observed or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory Activities. All safety data will be listed and summarised as appropriate.

Immunogenicity data (overall ADA incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies before the dose of MB02, EU Avastin® (Day -1) and at scheduled post-dose assessments will be presented by treatment arm. All safety data and immunogenicity data summaries will be based on the safety analysis population. Select analyses may be repeated for subsets with or without ADA and de novo ADA formation as appropriate.

02

Conditions studied

  • Healthy Volunteers
  • Male
  • Japanese
03

In context

Lead sponsor

mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

First submitted before mAbxience Research S.L. became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.
  2. Healthy Japanese males aged ≥20 to ≤55 years, inclusive, at Screening.
  3. Subjects with (BMI) between ≥18.5 to ≤28 kg/m2 and total body weight between ≥50 and ≤100 kg, at Screening
  4. Subject must have no abnormalities identified by a detailed medical history.
  5. Systolic blood pressure ≤140 mm Hg and diastolic blood pressure ≤90 mm Hg.
  6. Computerized (12-lead) (ECG) recording without signs of clinically relevant pathology.
  7. All other values for hematology, coagulation and for biochemistry and urinalysis tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator, according to the following laboratory values:

    Adequate bone marrow function

    • ≥1.5 × 109 L
    • count ≥100 × 109 L
    • >10 g/dl

    Adequate liver function:

    • (ALT) and aspartate aminotransferase (AST) ≤
    • Alkaline phosphatase (ALP) ≤1.5 × ULN
    • Total \<1.5 × ULN
    • Serum albumin: >3.5 g/dL
    • Low density lipoprotein cholesterol ≤139 mg/dL
    • High density lipoprotein cholesterol ≥ 40 mg/dL
    • Creatine kinase (CK) \<2 ULN at D-1

    Adequate coagulation:

    • (INR) 0.8 to 1.3

    Adequate renal function:

    • Blood urea nitrogen: ≤1.5 × ULN
    • Creatinine: \<1.5 mg/dL
    • Urine dipstick for proteinuria \<2+.
  8. All intermittent medications should have been stopped at least 30 days prior to admission to the clinical research center.
  9. Subjects agree to use .
  10. Ability and willingness to abstain from alcoholic beverages (alcohol) 48 hours prior to admission to the clinical research center.

Exclusion criteria

Exclusion Criteria:

  1. History of relevant allergy/ (including allergy to drug or its ).
  2. Previous treatment with an anti VEGF antibody like bevacizumab or any other protein or antibody targeting the VEGF receptor.
  3. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency.
  4. Known history of essential hypertension (subjects under any antihypertensive treatment included), orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions.
  5. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, diverticular disease, any fistulae, pulmonary hemorrhage (hemoptysis) or reversible posterior leukoencephalopathy syndrome.
  6. Any out-of-range laboratory values considered clinically significant by the investigator.
  7. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  8. Any current or recent history of active infections, including localized infections. (Within 2 months prior Screening Visit for any serious infection which requires hospitalization or intravenous anti-infective, and within 14 days prior Screening Visit for any active infection which requires oral treatment). A negative result for (HIV), (Hep B), and (Hep C) is required for participation. If subject shows positive Hepatitis B test, but results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator.
  9. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive urinary drug test screen and/or positive breath alcohol test at Screening or Check in. Average intake of more than 24 units of alcohol / wk. (1 unit of alcohol equals \~250mL of beer, 100mL of wine or 35mL of spirits). Positive urine drug screen (opiates, methadone, cocaine, amphetamines (including ecstasy or methamphetamines), cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and phencyclidine).
  10. Treatment with non-topical medications within 7 days prior to study drug administration, with the exception of hormonal , multivitamins, vitamin C, food supplements and a limited amount of acetaminophen, which may be used throughout the study.
  11. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 60 days prior to Check-in, or within 5 half lives of the investigational drug used in the study.
  12. Subjects considered unsuitable for inclusion by the investigator (e.g., inability to understand and comply with the study requirements or presence of any condition which, in the opinion of the investigator, would not allow safe participation in the study).
  13. Strenuous exercise within seven days prior to admission to the clinical research center.
  14. Significant or acute illness within 15 days prior to drug administration that may impact safety assessments per the judgement of the investigator.
  15. Unsuitable veins for infusion and/or venepuncture.
  16. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit. Presence of a nonhealing wound or fracture.
  17. Medically significant dental disease or dental neglect with signs and or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study.
  18. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  19. Have received a live or attenuated vaccine from 3 months prior to Screening or have the intention to receive a vaccine during the study.
  20. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing.
  21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or positive cotinine test upon Screening or Check-in.
  22. Receipt of blood products within 60 days prior to Check-in.
  23. Person who performed blood sampling more than 400 mL within 90 days before administration of investigational drug, more than 200 mL blood within 30 days, or blood donation of blood plasma / component within 14 days.
  24. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs.
  25. Have previously received Bevacizumab either under present study or under any other circumstances.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    MB02 (Bevacizumab Biosimilar)

    Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: MB02 (Bevacizumab Biosimilar)

  • Active comparator
    EU approved Avastin®

    Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: EU approved Avastin®

Interventions

  • Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion

  • DrugEU approved Avastin®

    Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]

    To compare the pharmacokinetic (PK) profiles of MB02 and EU Avastin® (in terms of AUC(0-∞)\]) in Japanese population to establish bioequivalence between the 2 study drugs.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    To evaluate and compare the Cmax of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  2. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)

    To evaluate and compare the AUClast of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  3. Time of Maximum Observed Serum Concentration (Tmax)

    To evaluate and compare the tmax of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  4. Apparent Serum Terminal Elimination Half Life (t1/2)

    To evaluate and compare the t1/2 of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  5. Total Body Clearance (CL)

    To evaluate and compare the CL of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  6. Volume of Distribution (Vz)

    To evaluate and compare the Vz of MB02 and EU Avastin® in Japanese population.

    Time frame: Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.

  7. Incidence of Treatment-related Adverse Events (Safety)

    Compare the incidence of TEAEs reported in each treatment arm using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: Day 1 - Day 70

  8. Incidence of ADA Including Nab (Immunogenicity)

    Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.

    Time frame: Day -1, Day 14, 28, 50 and 70.

07

Results

Posted Feb 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Started2425
Completed2424
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryArea Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]

To compare the pharmacokinetic (PK) profiles of MB02 and EU Avastin® (in terms of AUC(0-∞)\]) in Japanese population to establish bioequivalence between the 2 study drugs.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric least squares mean · ng*h/mL
Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]
ng*h/mLMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]30200000 ± 14.729000000 ± 10.8
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.04 · 90% CI 0.981 to 1.11
SecondaryMaximum Observed Serum Concentration (Cmax)

To evaluate and compare the Cmax of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric least squares mean · ng/mL
Maximum Observed Serum Concentration (Cmax)
ng/mLMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Maximum Observed Serum Concentration (Cmax)92900 ± 22.182300 ± 16.9
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.13 · 90% CI 1.03 to 1.24
SecondaryArea Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)

To evaluate and compare the AUClast of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric least squares mean · ng*h/mL
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)
ng*h/mLMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)28200000 ± 12.326800000 ± 9.18
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.05 · 90% CI 0.997 to 1.11
SecondaryTime of Maximum Observed Serum Concentration (Tmax)

To evaluate and compare the tmax of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Median · h
Time of Maximum Observed Serum Concentration (Tmax)
hMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Time of Maximum Observed Serum Concentration (Tmax)4.50 (1.52 to 24.00)4.00 (1.52 to 12.00)
SecondaryApparent Serum Terminal Elimination Half Life (t1/2)

To evaluate and compare the t1/2 of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric mean · h
Apparent Serum Terminal Elimination Half Life (t1/2)
hMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Apparent Serum Terminal Elimination Half Life (t1/2)430 ± 16.4450 ± 12.9
SecondaryTotal Body Clearance (CL)

To evaluate and compare the CL of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric mean · L/h
Total Body Clearance (CL)
L/hMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Total Body Clearance (CL)0.00660 ± 18.30.00702 ± 14.4
SecondaryVolume of Distribution (Vz)

To evaluate and compare the Vz of MB02 and EU Avastin® in Japanese population.

Time frame:
Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.
Reported as:
Geometric mean · L
Volume of Distribution (Vz)
LMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Volume of Distribution (Vz)4.10 ± 13.24.56 ± 12.5
SecondaryIncidence of Treatment-related Adverse Events (Safety)

Compare the incidence of TEAEs reported in each treatment arm using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

Time frame:
Day 1 - Day 70
Reported as:
Number · participants
Incidence of Treatment-related Adverse Events (Safety)
participantsMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
Subjects with TEAEs812
TEAEs of mild severity89
TEAEs of moderate severity26
TEAEs of severe severity00
Related TEAEs02
Subjects with SAEs00
Subjects discontinued due to TEAEs00
SecondaryIncidence of ADA Including Nab (Immunogenicity)

Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.

Time frame:
Day -1, Day 14, 28, 50 and 70.
Reported as:
Number · participants
Incidence of ADA Including Nab (Immunogenicity)
participantsMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
ADA positive01
nAb positive01
NO seroconversion2423

Adverse events

Collected over Day 1-Day 70. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MB02 (Bevacizumab Biosimilar)0/24 (0%)0/24 (0%)8/24 (33.3%)
EU Approved Avastin®0/24 (0%)0/24 (0%)12/24 (50%)
Most frequent other events
Most frequent other events
EventMB02 (Bevacizumab Biosimilar)EU Approved Avastin®
NasopharyngitisInfections and infestations2/246/24
PharyngitisInfections and infestations1/244/24
Blood Creatine Phosphokinase IncreasedInvestigations3/241/24
Alanine Aminotransferase IncreasedInvestigations2/242/24
Aspartate Aminotransferase IncreasedInvestigations2/241/24
Blood Lactate Dehydrogenase IncreasedInvestigations2/240/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®Total
Mean28.3 ± 5.928.5 ± 6.628.4 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®Total
Female000
Male242448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®Total
American Indian or Alaska Native000
Asian242448
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Weight
Weight(kg)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®Total
Mean67.0 ± 9.4868.5 ± 9.1367.75 ± 9.24
BMI
BMI(kg/m^2)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®Total
Mean22.54 ± 2.2623.33 ± 2.8422.94 ± 2.57
08

Study locations

1 site
  • SOUSEIKAI Hakata Clinic
    Fukuoka, 812-0025, Japan
09

References and documents

Publications

  • Eto T, Karasuyama Y, Gonzalez V, Del Campo Garcia A. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemother Pharmacol. 2021 Oct;88(4):713-722. doi: 10.1007/s00280-021-04324-z. Epub 2021 Jul 16. PubMed 34269848 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2019, 4 months.

Results were first posted in Feb 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 23, 2020
StartActual
Aug 2, 2019
Primary completionActual
Dec 27, 2019
CompletionActual
Dec 27, 2019
Results first posted
Feb 1, 2021
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04238650
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Aug 2, 2019
Primary completion
Dec 27, 2019
Completion
Dec 27, 2019
Results posted
Feb 1, 2021
Last update
Mar 23, 2021

Study contacts

Takashi ETO, MD
principal investigator · SOUSEIKAI Hakata Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MB02

Start the discussion